Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Obbina Abani, Ali Abbas, Fatima Abbas, et al.
The Lancet (2021) Vol. 397, Iss. 10285, pp. 1637-1645
Open Access | Times Cited: 1016

Showing 1-25 of 1016 citing articles:

Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial
Evdoxia Kyriazopoulou, Garyphallia Poulakou, Haralampos Milionis, et al.
Nature Medicine (2021) Vol. 27, Iss. 10, pp. 1752-1760
Open Access | Times Cited: 451
Pathophysiology of COVID-19-associated acute kidney injury
Matthieu Legrand, Samira Bell, Lui G. Forni, et al.
Nature Reviews Nephrology (2021) Vol. 17, Iss. 11, pp. 751-764
Open Access | Times Cited: 417
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial
Vincent C. Marconi, Athimalaipet V Ramanan, Stephanie de Bono, et al.
The Lancet Respiratory Medicine (2021) Vol. 9, Iss. 12, pp. 1407-1418
Open Access | Times Cited: 415
Therapeutic strategies for COVID-19: progress and lessons learned
Guangdi Li, Rolf Hilgenfeld, Richard J. Whitley, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 6, pp. 449-475
Open Access | Times Cited: 382
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Obbina Abani, Ali Abbas, Fatima Abbas, et al.
The Lancet (2022) Vol. 399, Iss. 10325, pp. 665-676
Open Access | Times Cited: 354
Effect of Noninvasive Respiratory Strategies on Intubation or Mortality Among Patients With Acute Hypoxemic Respiratory Failure and COVID-19
Gavin D. Perkins, Chen Ji, Bronwen Connolly, et al.
JAMA (2022) Vol. 327, Iss. 6, pp. 546-546
Open Access | Times Cited: 304
Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Michael J. Peluso, Scott Lu, Alex Tang, et al.
The Journal of Infectious Diseases (2021) Vol. 224, Iss. 11, pp. 1839-1848
Open Access | Times Cited: 261
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Obbina Abani, Ali Abbas, Fatima Abbas, et al.
The Lancet (2021) Vol. 399, Iss. 10320, pp. 143-151
Open Access | Times Cited: 257
A blood atlas of COVID-19 defines hallmarks of disease severity and specificity
David Ahern, Zhichao Ai, Mark Ainsworth, et al.
Cell (2022) Vol. 185, Iss. 5, pp. 916-938.e58
Open Access | Times Cited: 254
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
Obbina Abani, Ali Abbas, Fatima Abbas, et al.
The Lancet (2022) Vol. 400, Iss. 10349, pp. 359-368
Open Access | Times Cited: 254
Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium
Diana A. Gorog, Robert F. Storey, Paul A. Gurbel, et al.
Nature Reviews Cardiology (2022) Vol. 19, Iss. 7, pp. 475-495
Open Access | Times Cited: 251
Cytokine Storm in COVID-19: Immunopathogenesis and Therapy
Christian Zanza, Tatsiana Romenskaya, A Manetti, et al.
Medicina (2022) Vol. 58, Iss. 2, pp. 144-144
Open Access | Times Cited: 240
American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV‐2 and Hyperinflammation in Pediatric COVID‐19: Version 3
Lauren A. Henderson, Scott W. Canna, Kevin G. Friedman, et al.
Arthritis & Rheumatology (2022) Vol. 74, Iss. 4
Open Access | Times Cited: 238
Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19
Ryan S. Thwaites, Ashley Sanchez Sevilla Uruchurtu, Matthew K. Siggins, et al.
Science Immunology (2021) Vol. 6, Iss. 57
Open Access | Times Cited: 214
COVID-19 and metabolic disease: mechanisms and clinical management
Charlotte Steenblock, Peter E. H. Schwarz, Barbara Ludwig, et al.
The Lancet Diabetes & Endocrinology (2021) Vol. 9, Iss. 11, pp. 786-798
Open Access | Times Cited: 206
Interplay between interleukin-6 signaling and the vascular endothelium in cytokine storms
Sujin Kang, Tadamitsu Kishimoto
Experimental & Molecular Medicine (2021) Vol. 53, Iss. 7, pp. 1116-1123
Open Access | Times Cited: 205
Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection
Yu‐Chyi Hwang, Ruei‐Min Lu, Shih-Chieh Su, et al.
Journal of Biomedical Science (2022) Vol. 29, Iss. 1
Open Access | Times Cited: 194
Latent Class Analysis Reveals COVID-19–related Acute Respiratory Distress Syndrome Subgroups with Differential Responses to Corticosteroids
Pratik Sinha, David Furfaro, Matthew J. Cummings, et al.
American Journal of Respiratory and Critical Care Medicine (2021) Vol. 204, Iss. 11, pp. 1274-1285
Open Access | Times Cited: 193
Host genetic factors determining COVID-19 susceptibility and severity
Thirumalaisamy P. Velavan, Srinivas Reddy Pallerla, Jule Rüter, et al.
EBioMedicine (2021) Vol. 72, pp. 103629-103629
Open Access | Times Cited: 182
Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

The Lancet Respiratory Medicine (2021) Vol. 9, Iss. 12, pp. 1419-1426
Open Access | Times Cited: 171
Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial
E. Wesley Ely, Athimalaipet V Ramanan, Cynthia E. Kartman, et al.
The Lancet Respiratory Medicine (2022) Vol. 10, Iss. 4, pp. 327-336
Open Access | Times Cited: 167
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations
Rebecca Grainger, Alfred H.J. Kim, Richard Conway, et al.
Nature Reviews Rheumatology (2022) Vol. 18, Iss. 4, pp. 191-204
Open Access | Times Cited: 159
Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19
Roberto Caricchio, Antonio Abbate, И. Г. Гордеев, et al.
JAMA (2021) Vol. 326, Iss. 3, pp. 230-230
Open Access | Times Cited: 157
Innate immune evasion strategies of SARS-CoV-2
Judith M. Minkoff, Benjamin R. tenOever
Nature Reviews Microbiology (2023)
Open Access | Times Cited: 157
Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis
Evdoxia Kyriazopoulou, Thomas Huet, Giulio Cavalli, et al.
The Lancet Rheumatology (2021) Vol. 3, Iss. 10, pp. e690-e697
Open Access | Times Cited: 152
Page 1 - Next Page

Scroll to top